Eli Lilly's Trading Volume Surges 45.68% to 27.40 Billion, Ranks 20th in Market as it Acquires SiteOne Therapeutics for Up to 1 Billion

On May 27, 2025, Eli Lilly's trading volume reached 27.40 billion, marking a 45.68% increase from the previous day, placing it 20th in the day's stock market rankings.

Eli Lilly has agreed to acquire SiteOne Therapeutics, a privately held biopharma company, for up to $1 billion in cash. This acquisition includes an upfront payment and subsequent milestone payments. The deal brings SiteOne's flagship product, STC-004, a Phase 2 ready Nav1.8 inhibitor, into Eli Lilly's pipeline. STC-004 is being developed as a non-opioid-based pain treatment, aiming to advance new medicines for pain management.

With this acquisition, Eli Lilly gains access to a promising non-opioid pain treatment, which aligns with the company's strategy to expand its pain management pipeline. The addition of STC-004 to Eli Lilly's portfolio is expected to enhance its capabilities in developing innovative pain management solutions.